Our Products

ORLADEYO® (berotralstat)

ORLADEYO® (berotralstat) is an oral, once-daily capsule that prevents hereditary angioedema (HAE) attacks by inhibiting plasma kallikrein. ORLADEYO is approved in the United States, the European Union, Japan and the United Kingdom for the prevention of HAE attacks in adults and pediatric patients 12 years and older. It is not known if ORLADEYO is safe and effective to treat an acute HAE attack, therefore ORLADEYO should not be used to treat an acute HAE attack. For additional information, please visit www.ORLADEYO.com, and for full U.S. prescribing information, click here.